Full Text View
Tabular View
No Study Results Posted
Related Studies
Effectiveness of KOS-862 in the Treatment of Lung Cancer
This study has been terminated.
Study NCT00080509   Information provided by Bristol-Myers Squibb
First Received: April 5, 2004   Last Updated: January 20, 2009   History of Changes

April 5, 2004
January 20, 2009
December 2003
 
NSCLC
Same as current
Complete list of historical versions of study NCT00080509 on ClinicalTrials.gov Archive Site
 
 
 
Effectiveness of KOS-862 in the Treatment of Lung Cancer
A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease

The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.

To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following initial chemotherapy for advanced or metastatic disease.

Phase II
Interventional
Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Lung Cancer
Drug: KOS-862
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Terminated
85
November 2004
 

Inclusion Criteria:

  • At least 18 years of age
  • Measurable disease
  • One previous treatment of a platinum based drug such as cisplatin or carboplatin
  • At least 3 weeks since last surgery/radiation/chemotherapy

Exclusion Criteria:

  • Brain metastases
  • Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00080509
 
KOS-201/NO17352
Bristol-Myers Squibb
 
 
Bristol-Myers Squibb
December 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP